What Characteristics at Baseline Are Associated with the Glucose-Lowering Effect of Colestimide in Patients with Type 2 Diabetes with Hypercholesterolemia?

被引：0
|
作者：
Suzuki, Tatsuya
Watanabe, Kentaro
Ouchi, Motoshi
Suzuki, Kazunari
Sekimizu, Kenichi
Nakano, Hiroshi
Oba, Kenzo
机构：
来源：
DIABETES | 2011年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2354-PO
引用
收藏
页码：A626 / A626
页数：1
相关论文
共 50 条
  • [31] Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes
    Kalyani, Rita R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (13): : 1248 - 1260
  • [32] Newer Glucose-Lowering Therapies in Older Adults with Type 2 Diabetes
    Bilal, Anika
    Pratley, Richard E.
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2023, 52 (02) : 355 - 375
  • [33] The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
    C. J. Currie
    C. D. Poole
    E. A. M. Gale
    Diabetologia, 2009, 52 : 1766 - 1777
  • [34] Impact of glucose-lowering therapies on risk of stroke in type 2 diabetes
    Bonnet, F.
    Scheen, A. J.
    DIABETES & METABOLISM, 2017, 43 (04) : 299 - 313
  • [35] Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes
    Ferrannini, Ele
    DeFronzo, Ralph A.
    EUROPEAN HEART JOURNAL, 2015, 36 (34) : 2288 - U19
  • [36] Effectiveness of glucose-lowering therapy in type 2 diabetes in primary care
    Jacobs, Esther
    Kostev, Karel
    Rathmann, Wolfgang
    DIABETOLOGE, 2019, 15 (02): : 89 - 95
  • [37] Role of bile acids on glucose-lowering by metformin in type 2 diabetes
    Sansome, D. J.
    Veedfald, S.
    Xie, C.
    Bound, M.
    Grivell, J.
    Jones, K. L.
    Horowitz, M.
    Rayner, C. K.
    Wu, T.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S14 - S15
  • [38] The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
    Currie, C. J.
    Poole, C. D.
    Gale, E. A. M.
    DIABETOLOGIA, 2009, 52 (09) : 1766 - 1777
  • [39] COST OF TYPE 2 DIABETES ACCORDING TO GLUCOSE-LOWERING MEDICATIONS IN FRANCE
    Charbonnel, B.
    Dallongeville, J.
    Simon, D.
    Bureau, I
    Leproust, S.
    Levy-Bachelot, I
    Gourmelen, J.
    Detournay, B.
    VALUE IN HEALTH, 2015, 18 (07) : A604 - A604
  • [40] Initial glucose-lowering therapy and cardiovascular outcomes in type 2 diabetes
    Misnikova, I. V.
    Dreval, A. V.
    Kovaleva, Y. A.
    DIABETOLOGIA, 2012, 55 : S326 - S326
12345